MedPath

The role of lumbar lordosis rehabilitation in patients with discogenic lumbosacral radiculopathy: A randomized trial

Completed
Conditions
discogenic lumbosacral radiculopathy
Musculoskeletal - Other muscular and skeletal disorders
Physical Medicine / Rehabilitation - Physiotherapy
Registration Number
ACTRN12612000311853
Lead Sponsor
Ibrahim Moustafa Moustafa
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
64
Inclusion Criteria

patients with absolute rotatory angle was less than 39 degrees. then a participant was referred to the study. patients had a confirmed chronic unilateral lumbosacral radiculopathy associated with L5-S1 lumbar disc prolapse , and duration of symptoms more than 3 months to avoid acute stage of inflammation. Patients underwent magnetic resonance (MR) imaging, which detected disc lesion corresponding to the S1 nerve root. All patients had unilateral leg pain with mild to moderate disability according to ODI (up to 40%). They all had side-to-side H reflex latency differences of more than 1msec.

Exclusion Criteria

included previous history of lumbosacral surgery, metabolic system disorder, cancer, cardiac problems, peripheral neuropathy or history of upper motor neuron lesion, spinal canal stenosis, rheumatoid arthritis, osteoprosis, inability to tolerate lumbar extension position, spondylolisthesis , scoliotic deformity and any deformity of lower extremity that may interfere with global alignment.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
the lumbar lordotic angle.it was measured from lateral radiograph by calculating the ARA which considered as a valid and reliable measurement. From lateral radiograph, the posterior superior and posterior inferior vertebral body corners of L1 and L5on lateral lumbar radiograph were marked. The absolute rotatory angle formed by the intersection between posterior vertebral body tangent lines of L1 and L5.[pre treatment, 10 weeks post treatment, and at six months of follow up]
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath